AB
LBRX

Amalgamated Bank’s LB Pharmaceuticals LBRX Stock Holding History

Amalgamated Bank’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-605
Closed -$13K – 2973
2025
Q4 		$13K Buy
+605
New +$10.6K ﹤0.01% 2325

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Amalgamated Bank's LBRX Position: Q1 2026 in Review

Amalgamated Bank sold out of LB Pharmaceuticals (LBRX) in Q1 2026, closing a stake of 605 shares — an estimated $13K sold.

Amalgamated Bank first reported a position in LBRX in Q4 2025 and held it in 1 quarter. The position peaked at $13K in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Amalgamated Bank reported no remaining LB Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 605 LB Pharmaceuticals shares in Q1 2026, an estimated $13K.
  • Amalgamated Bank first reported a position in LB Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Amalgamated Bank's LB Pharmaceuticals position peaked at $13K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.